SCHEMBL2270309

SCHEMBL2270309

O=C(Nc1cc(N2CCC(C(=O)c3ccccc3)CC2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 3/20 0.50
GRIK1 P39086 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CPB1 P15086 1/20 0.49
MALT1 Q9UDY8 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
PLA2G1B P04054 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
SERPINE1 P05121 2/20 0.46
GPR6 P46095 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275234 0.86 MALT1 (0.51) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL2276799 0.83 MALT1 (0.52) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL2273832 0.77 PPARG (0.54) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL2268310 0.75 MAPT (0.48) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL2273168 0.75 SERPINE1 (0.61) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL845869 0.73 KDR (0.64) PKMSMN1; SMN2USP2ALDH1A1HPGD
SCHEMBL14428266 0.73 IP6K1 (0.45) PKMMEN1KMT2AMAPTMALT1
SCHEMBL2273007 0.73 MALT1 (0.45) PKMMEN1KMT2AMAPTMALT1
SCHEMBL2269025 0.72 MAPT (0.50) PKMMEN1KMT2AMAPTGRIK1
SCHEMBL2272642 0.71 HDAC1 (0.59) MEN1KMT2AMAPTSERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PKM 2367/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.